Your browser doesn't support javascript.
loading
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar, Angela; Morris, Bonny B; Desnoyer, Rodwige; Klepin, Heidi D; Hosseinzadeh, Keyanoosh; Clark, Clancy; Cameron, Amy; Leyendecker, John; D'Agostino, Ralph; Topaloglu, Umit; Boteju, Lakmal W; Boteju, Asela R; Shorr, Rob; Zachar, Zuzana; Bingham, Paul M; Ahmed, Tamjeed; Crane, Sandrine; Shah, Riddhishkumar; Migliano, John J; Pardee, Timothy S; Miller, Lance; Hawkins, Gregory; Jin, Guangxu; Zhang, Wei; Pasche, Boris.
Afiliación
  • Alistar A; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Electronic address: angela.alistar@atlantichealth.org.
  • Morris BB; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Desnoyer R; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Klepin HD; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Hosseinzadeh K; Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Clark C; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Section on Surgical Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Cameron A; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Leyendecker J; UT Southwestern Medical Center, Department of Radiology, Dallas, TX, USA.
  • D'Agostino R; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Biostatistics, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Topaloglu U; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Boteju LW; Department of Chemistry, Cornerstone Pharmaceuticals, Cranbury, NJ, USA.
  • Boteju AR; Department of Chemistry, Cornerstone Pharmaceuticals, Cranbury, NJ, USA.
  • Shorr R; Department of Chemistry, Cornerstone Pharmaceuticals, Cranbury, NJ, USA.
  • Zachar Z; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, USA.
  • Bingham PM; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, USA.
  • Ahmed T; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Crane S; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Shah R; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Migliano JJ; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Pardee TS; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest University School of
  • Miller L; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Hawkins G; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Jin G; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Zhang W; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Pasche B; Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest University School of
Lancet Oncol ; 18(6): 770-778, 2017 06.
Article en En | MEDLINE | ID: mdl-28495639
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Enfermedades Hematológicas Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Enfermedades Hematológicas Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido